Google
SNY 株価分析 — SANOFI ADR (Healthcare >> Drug Manufacturers - General)
SNY に関するよくある質問
SNYのPER（株価収益率）は？
SANOFI ADR（SNY）は現在PER 21.59倍で取引されています。
SNYのROE（自己資本利益率）は？
SANOFI ADRのROEは5.72%です。
SNYの配当利回りは？
SANOFI ADRの配当利回りは0.00%です。
SNYの品質スコア（Quality Score）は？
当社のAIはSNYの総合財務品質を100点中31点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
SNYは今が買い時ですか？
当社AIのタイミングスコアは100点中27点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
SNYはどのセクターに属しますか？
SANOFI ADRはHealthcare >> Drug Manufacturers - Generalセクターに分類されます（NASDAQ市場）
SNY AI Analysis Summary
Our AI summary for SNY: SANOFI ADR (NASDAQ), Healthcare >> Drug Manufacturers - General sector. The stock currently trades at a P/E of 21.59, ROE of 5.72%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 43.08
Price
0.19
(0.44%)
Day Change
|
|
|---|
SNY, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROEの伸びが低い
平均ROEが低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 86 |
| Magic Formula Rank by ROA |
1386
|
| Magic Formula Rank by ROE |
1386
|
| Magic Formula Rank by ROIC |
2139
|
| Price | 43.08 |
| PBV / Sector |
1.48 / 2.68
GOOD
|
| Earning Per Share | 1.66 |
| PE / Sector |
21.59 / 27.65
|
| PEG or PE/Growth / Sector |
5.52 / 0.28
|
| Average 1M Daily Value |
149.88 M
GREAT
|
| Average 1W Daily Value |
196.05 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
52% |
| ポイントになる統計 |
|
60% |
| 配当 |
|
33% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:30 |
| Symbol | SNY |
| Name | SANOFI ADR |
| Sector | Healthcare >> Drug Manufacturers - General |
| Market | NASDAQ |
| Listed Shares | 2,396.14 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 102,770.34 / 256,404.20 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 46, avenue de la Grande ArmEe, Paris, France, 75017
Phone: 33 1 53 77 40 00
Website: https://www.sanofi.com
Employees: 74,846
Description: Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - General
Click a bubble to view stock details · Bubble size represents market capitalization share
